Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bart Heeg

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
Leukemia & Lymphoma|November 6, 2019
A matching-adjusted indirect treatment comparison (MAIC) of daratumumab-bortezomib-melphalan-prednisone (D-VMP) versus lenalidomide-dexamethasone continuous (Rd continuous), lenalidomide-dexamethasone 18 months (Rd 18), and melphalan-prednisone-thalidomide (MPT)Meletios A Dimopoulos, Michele Cavo, Maria-Victoria Mateos, et al.
Advances in Therapy|October 17, 2020
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching AnalysisVania Hungria, Deborah M Martínez-Baños, María-Victoria Mateos, et al.
Ejhaem|July 18, 2022
Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D-VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant-eligible patients with newly diagnosed multiple myeloma, using propensity score matchingPhilippe Moreau, Cyrille Hulin, Sonja Zweegman, et al.
Pharmacoeconomics - Open|February 22, 2023
Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung CancerAndre Verhoek, Parneet Cheema, Barbara Melosky, et al.
Advances in Therapy|July 3, 2024
Feasibility of Indirect Treatment Comparisons Between Niraparib Plus Abiraterone Acetate and Other First-Line Poly ADP-Ribose Polymerase Inhibitor Treatment Regimens for Patients with BRCA1/2 Mutation-Positive Metastatic Castration-Resistant Prostate CancerMaria De Santis, Sara Martínez Breijo, Paul Robinson, et al.
Blood Advances|December 7, 2020
A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myelomaNikhil C Munshi, Herve Avet-Loiseau, Kenneth C Anderson, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
Leukemia & Lymphoma|November 6, 2019
A matching-adjusted indirect treatment comparison (MAIC) of daratumumab-bortezomib-melphalan-prednisone (D-VMP) versus lenalidomide-dexamethasone continuous (Rd continuous), lenalidomide-dexamethasone 18 months (Rd 18), and melphalan-prednisone-thalidomide (MPT)Meletios A Dimopoulos, Michele Cavo, Maria-Victoria Mateos, et al.
Advances in Therapy|October 17, 2020
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching AnalysisVania Hungria, Deborah M Martínez-Baños, María-Victoria Mateos, et al.
Ejhaem|July 18, 2022
Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D-VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant-eligible patients with newly diagnosed multiple myeloma, using propensity score matchingPhilippe Moreau, Cyrille Hulin, Sonja Zweegman, et al.
Pharmacoeconomics - Open|February 22, 2023
Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung CancerAndre Verhoek, Parneet Cheema, Barbara Melosky, et al.
Advances in Therapy|July 3, 2024
Feasibility of Indirect Treatment Comparisons Between Niraparib Plus Abiraterone Acetate and Other First-Line Poly ADP-Ribose Polymerase Inhibitor Treatment Regimens for Patients with BRCA1/2 Mutation-Positive Metastatic Castration-Resistant Prostate CancerMaria De Santis, Sara Martínez Breijo, Paul Robinson, et al.
Blood Advances|December 7, 2020
A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myelomaNikhil C Munshi, Herve Avet-Loiseau, Kenneth C Anderson, et al.
Pageof 5